Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
|
IN |
Balance Sheet
Balance Sheet Decomposition
Akums Drugs and Pharmaceuticals Ltd
Akums Drugs and Pharmaceuticals Ltd
Balance Sheet
Akums Drugs and Pharmaceuticals Ltd
| Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|
| Assets | |||||
| Cash & Cash Equivalents |
551
|
516
|
1 111
|
1 012
|
|
| Cash |
483
|
516
|
489
|
825
|
|
| Cash Equivalents |
68
|
0
|
621
|
187
|
|
| Short-Term Investments |
482
|
989
|
1 768
|
4 808
|
|
| Total Receivables |
10 293
|
9 597
|
9 831
|
9 930
|
|
| Accounts Receivables |
8 843
|
8 451
|
8 338
|
7 703
|
|
| Other Receivables |
1 450
|
1 146
|
1 493
|
2 227
|
|
| Inventory |
7 224
|
7 545
|
6 505
|
6 809
|
|
| Other Current Assets |
366
|
595
|
194
|
187
|
|
| Total Current Assets |
18 916
|
19 242
|
19 409
|
22 746
|
|
| PP&E Net |
10 439
|
11 925
|
13 772
|
15 498
|
|
| PP&E Gross |
10 439
|
11 925
|
13 772
|
15 498
|
|
| Accumulated Depreciation |
4 603
|
5 394
|
6 470
|
7 837
|
|
| Intangible Assets |
56
|
59
|
69
|
83
|
|
| Goodwill |
21
|
21
|
21
|
21
|
|
| Note Receivable |
638
|
708
|
295
|
317
|
|
| Long-Term Investments |
164
|
78
|
38
|
36
|
|
| Other Long-Term Assets |
456
|
632
|
1 560
|
2 434
|
|
| Other Assets |
21
|
21
|
21
|
21
|
|
| Total Assets |
30 690
N/A
|
32 665
+6%
|
35 164
+8%
|
41 134
+17%
|
|
| Liabilities | |||||
| Accounts Payable |
5 897
|
5 671
|
5 321
|
6 428
|
|
| Accrued Liabilities |
333
|
371
|
488
|
484
|
|
| Short-Term Debt |
3 427
|
3 913
|
3 677
|
137
|
|
| Current Portion of Long-Term Debt |
133
|
412
|
513
|
72
|
|
| Other Current Liabilities |
2 934
|
2 289
|
2 106
|
1 817
|
|
| Total Current Liabilities |
12 724
|
12 656
|
12 106
|
8 937
|
|
| Long-Term Debt |
437
|
1 904
|
1 462
|
673
|
|
| Deferred Income Tax |
393
|
253
|
122
|
186
|
|
| Minority Interest |
32
|
62
|
110
|
166
|
|
| Other Liabilities |
10 884
|
10 619
|
14 270
|
701
|
|
| Total Liabilities |
24 471
N/A
|
25 493
+4%
|
28 069
+10%
|
10 664
-62%
|
|
| Equity | |||||
| Common Stock |
143
|
286
|
286
|
306
|
|
| Retained Earnings |
4 805
|
5 614
|
5 537
|
19 324
|
|
| Additional Paid In Capital |
1 272
|
1 272
|
1 272
|
10 840
|
|
| Total Equity |
6 220
N/A
|
7 172
+15%
|
7 095
-1%
|
30 470
+329%
|
|
| Total Liabilities & Equity |
30 690
N/A
|
32 665
+6%
|
35 164
+8%
|
41 134
+17%
|
|
| Shares Outstanding | |||||
| Common Shares Outstanding |
157
|
157
|
157
|
153
|
|